ArticleRadiation oncology journal2026
Efficacy and safety of single-fraction radiosurgery in vestibular schwannoma: a 10-year experience.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Frameless gamma knife stereotactic radiosurgery for over two hundred vestibular schwannoma patients - a single institution experience.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate long-term tumor control, safety, and prognostic factors following single-fraction stereotactic radiosurgery (SRS) for vestibular schwannoma (VS). MATERIALS AND
methodsIn this retrospective single-institution study, 68 patients with VS were treated with photon-based single-fraction SRS (mean dose, 13.1 Gy; range, 12 to 15 Gy). Treatment planning was based on computed tomography-magnetic resonance imaging (MRI) fusion with organ-at-risk sparing and a planning target volume margin of 0-2 mm. The primary endpoint was local control (LC). Secondary endpoints included toxicity and predictors of treatment failure.
resultsAfter a median follow-up of 68 months, LC was maintained in 95.6% of patients. Actuarial LC rates at 5 and 10 years were both 98.5%. MRI showed tumor shrinkage in 41.2% and stability in 57.4% of cases. Treatment was well tolerated. Acute adverse events were infrequent and mild. Localized alopecia occurred acutely in one patient (1.5%) and did not persist into late follow-up. Vertigo and tinnitus were analyzed as disease-related symptoms rather than treatment-related toxicities. Severe toxicity (grade ≥ 3) was rare (<3%). Cox regression revealed no statistically significant predictors of local failure, though trends suggested higher risk after prior surgery and with doses ≥14 Gy.
conclusionSingle-fraction SRS provides durable long-term LC of VS with a favorable toxicity profile, supporting its role as a primary treatment modality. Optimal outcomes appear to be associated with lower prescription doses (<14 Gy) and treatment of de novo tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.